Cardarine (GW-501516): A Tracking Guide for a PPAR-Delta Agonist

Cardarine, developed as GW-501516, is a PPAR-delta agonist. It is often grouped with SARMs and sold alongside them, but it is not a SARM and does not act on the androgen receptor. It shifts metabolism toward fat oxidation and is used for endurance and fat loss.

The most important fact about cardarine comes first: GlaxoSmithKline halted its development in 2007 after a long-term rodent carcinogenicity study showed tumors developing in multiple organ systems, including liver, stomach, skin, and bladder, at high doses. This guide is written as harm-reduction tracking for people who have already decided to use it, not as a recommendation, and it is not medical advice.

What it is

• A PPAR-delta agonist that upregulates fat-burning and endurance-related gene expression
• Not androgenic and not hormonally suppressive on its own
• An abandoned drug candidate with no approved human use

What it does

• Increases fatty acid oxidation and metabolic rate
• Improves reported exercise endurance and work capacity
• Does not build muscle directly

Typical protocol shape

• Taken orally, once daily, over a short defined block
• Doses and durations commonly reported in research literature; this guide does not prescribe one
• Frequently paired with training focused on endurance or fat loss

What to track daily

• Endurance and perceived exertion during cardio
• Bodyweight and appetite
• Energy and recovery

What to track weekly

• Waist and bodyweight trend
• Conditioning benchmarks such as time or distance
• General well-being

Bloodwork worth doing

• A lipid panel and metabolic panel for a baseline
• A liver panel, given the organ findings in animal studies

Realistic expectations

• Endurance and fat-oxidation effects can be noticeable
• No direct muscle-building effect
• The rodent cancer signal is the dominant unknown for long-term human risk

Safety notes

The defining concern is the rodent carcinogenicity that ended clinical development; no long-term human safety data exists because the trials never got that far. Anyone using it is accepting an unquantified cancer risk. It is also an unregulated research chemical, so mislabeling and contamination add further uncertainty. The honest harm-reduction position is to keep any exposure minimal, brief, and fully informed.

Peptid AI is an educational and self-tracking tool. Nothing in this post is medical advice. Doses mentioned reflect what is commonly reported in research literature — they are not recommendations. Always consult a qualified physician before starting, changing, or stopping any protocol.